Active material: Guanfaцin
When ATH: C02AC02
CCF: Stimulant of the central alpha2-adrenoreceptorov. Antihypertensive drugs
When CSF: 01.09.01.01
Manufacturer: EGIS PHARMACEUTICALS Plc (Hungary)
PHARMACEUTICAL FORM, COMPOSITION AND PACKAGING
Pills white or yellowish white, round, flat, chamfered, with Valium on one side and engraved with the stylized letter E on the other side; with little or no odor.
|guanfatsina hydrochloride||1.15 mg,|
|that corresponds to the content guanfatsina||1 mg|
Excipients: lactose monohydrate, microcrystalline cellulose, povidone, stearic acid.
10 PC. – blisters (2) – packs cardboard.
Antihypertensive drugs. The mechanism of action is associated with the stimulation of a central2-adrenoreceptorov, which leads to a reduction of the sympathetic tone. The result is a reduction in systemic vascular resistance and decreases in blood pressure.
Estulik no effect on the activity of the heart. The decrease in heart rate is offset by an increase in systolic volume. It does not affect the mechanisms regulating blood pressure or resting, or during exercise.
The drug does not cause changes in renal function: sodium retention is not observed, water, there is no excessive excretion of potassium. Glomerular filtration rate remains constant even in patients with clinical signs of renal failure. It reduces plasma renin activity.
The antihypertensive effect of long-term.
Arterial hypertension (as monotherapy or in combination therapy), including:
- Primary hypertension;
- Renovascular hypertension.
In the case of severe hypertension tablets Estulik combination with diuretics may be supplemented by a beta blocker or a vasodilator. Due to the pharmacological properties of the drug, hypertensive patients, suffering from obstructive pulmonary disease and respiratory tract, heart failure or renal insufficiency, and AV blockade degree I tolerate Estulik.
Adults at the beginning of the treatment drug is prescribed in a dose 0.5-1 mg (1/2-1 tab.) 1 time / day. If necessary, the dose may be increased to 0.5-1 mg / day at intervals of not less than 1 weeks to achieve the desired level of blood pressure. The average effective dose is 2-3 mg.
Estulik be taken 1 time / day before bedtime.
If BP does not decrease during monotherapy, Additionally, you can assign diuretics, vasodilators, beta-blockers with ISA (pindolol, oxprenolol).
In patients severe renal insufficiency, not on dialysis, the daily dose should be reduced.
From the digestive system: available (especially at high initial doses or a sharp increase in dose) dry mouth; in some cases – loss of appetite, nausea.
CNS: possible (especially at high initial doses or a sharp increase in dose) sedation, feeling tired, drowsiness, headache; in some cases – confusion.
Other: in some cases – impotence.
Most side effects, usually, passes with continued treatment.
- Hypersensitivity to guanfacine and other ingredients.
It is not recommended for the treatment of patients with AV block II and III degree (tk. Information on the safety of the drug in these patients is not enough).
Pregnancy and lactation
Use in pregnancy and lactation is possible in cases, when the expected benefit of therapy for the mother outweighs the potential risk to the fetus or infant.
Data, confirming any negative effect of the drug on the fetus Estulik or missing newborn.
IN experimental studies revealed no teratogenic effect of the drug.
With caution and under constant medical supervision should be given Estulik patients with cerebrovascular or coronary insufficiency, especially when specifying a history of stroke or severe heart disease.
While withdrawal symptoms are rare, Treatment should be stopped slowly and gradually.
Avoid the simultaneous use of a Estulika antagonists2-adrenoreceptorov (phentolamine, joximʙin).
It should be used with caution in the drug simultaneously with sympathomimetic agents, блокаторами b-адренорецепторов, neuroleptics.
IN experimental studies received data, attesting to the absence of any restrictions on the use of the drug in humans Estulik. In studies in mice and rats revealed no carcinogenic effects of the drug.
Effects on ability to drive vehicles and management mechanisms
Estulik may cause deterioration of the patient's psychomotor reactions. In this regard, it is not recommended driving operation of motor vehicles and potentially dangerous equipment for some time at the initial stage of treatment, or in case of increasing doses (This period depends on the individual patient's response to treatment).
Symptoms: possible drowsiness, hypotension, bradycardia.
Treatment: symptomatic therapy, gastric lavage, if appropriate infusion izuprela, monitoring the patient's condition.
The drug does not appear during dialysis.
Antagonists of a2-adrenoreceptorov (phentolamine, ioximʙin) reduce the effect of Estulika.
In an application with the action of sympathomimetic agents decreases Estulika.
When concomitant administration Estulika with beta-blockers may decrease the excessive heart rate. It is less likely when using the drug in combination with beta-blockers with ISA.
In an application Estulika with neuroleptics may increase sedation.
Pharmaceutical incompatibility of the drug is not known Estulik.
Conditions and terms
The drug should be stored under normal conditions at room temperature (from 15° to 25°C). Shelf life – 3 year.
Conditions of supply of pharmacies
The drug is released under the prescription.